NCT03413410 is a NA clinical trial of Metoprolol in ACS - Acute Coronary Syndrome, sponsored by Yun Dai Chen.

Who is sponsoring NCT03413410?

NCT03413410 is sponsored by Yun Dai Chen.

What drugs are being tested in NCT03413410?

Interventions in NCT03413410: Metoprolol.

What condition does NCT03413410 study?

NCT03413410 studies ACS - Acute Coronary Syndrome.

Is NCT03413410 still recruiting?

NCT03413410 is currently status unknown. Last updated 19 July 2019.

Last reviewed 2019-07-19 · How we verify

NCT03413410

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome

Status unknown NA Last updated 19 July 2019

What this trial tests

NA trial testing Metoprolol in ACS - Acute Coronary Syndrome in 1,000 participants. Status unknown.

Timeline

1 February 2018

Primary endpoint
30 July 2019

30 July 2020

Quick facts

Lead sponsor	Yun Dai Chen
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1,000
Start date	1 February 2018
Primary completion	30 July 2019
Estimated completion	30 July 2020
Sites	1 location across China

Drugs / interventions tested

Metoprolol (metoprolol) — full drug profile →

Conditions studied

ACS - Acute Coronary Syndrome — all drugs for ACS - Acute Coronary Syndrome →

Sponsor

Yun Dai Chen — full company profile →

Who can join

Adults 18 to 80, any sex, with ACS - Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to test the feasibility and tolerability of the metoprolol optimal dosing pathway by observing the percentage of patients achieving target dose followed the pathway on ACS patients during hospitalization.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluation of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: a prospective multicenter single-arm interventional study.
Yin XY, Zhang YM, Shen AD, Wang JP, et al · · 2023 · cited 1× · PMID 37122993 · DOI 10.26599/1671-5411.2023.04.001
Impact of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: protocol for a multicentre prospective study.
Li D, Dong W, Liu Y, Wang J, et al · · 2019 · cited 1× · PMID 31806613 · DOI 10.1136/bmjopen-2019-031972

Verify or expand the search:

Other trials of Metoprolol

Trials testing the same drug.

NCT06808802 — To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants · Phase 1 · completed
NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates · Phase 1 · active not recruiting
NCT06357104 — Detoxification From the Lipid Tract · Phase 4 · completed
NCT05741385 — A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by t · NA · completed
NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) S · EARLY_PHASE1 · completed

Other recruiting trials for ACS - Acute Coronary Syndrome

Currently open trials in the same condition.

NCT07064109 — Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients · NA · recruiting
NCT07283809 — European Unified Registries for Heart Care Evaluation and Randomised Trials Italy · recruiting
NCT06283888 — CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention · Phase 4 · recruiting

Other Yun Dai Chen trials

Trials by the same sponsor.

NCT06854523 — Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI) · NA · not yet recruiting
NCT06738758 — Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of · recruiting
NCT06567418 — Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03413410 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yun Dai Chen
Last refreshed: 19 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03413410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing